Drug Profile
Itraconazole inhaled - Cipla/Pulmatrix
Alternative Names: Itraconazole Powder; Pulmazole; PUR 1900Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Pulmatrix
- Class Antiasthmatics; Antifungals; Antineoplastics; Azoles; Chlorobenzenes; Dioxoles; Piperazines; Small molecules; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors; Hedgehog cell-signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Aspergillosis; Asthma
Most Recent Events
- 27 Feb 2024 Pulmatrix terminates a phase II trial for Aspergillosis in USA, Australia, France and the United Kingdom (Inhalation, Powder), due to low enrollment (NCT05667662)
- 08 Jan 2024 Pulmatrix entered into a further amendment to its agreement with Cipla for the development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA)
- 08 Jan 2024 Pulmatrix stops a phase II trial for Aspergillosis in USA, Australia, the United Kingdom and France (NCT05667662)